This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).
Age > 18 years.
Histologically confirmed diagnosis of multiple myeloma with evidence of progressive disease as defined by the IMWG criteria.
Serum M-protein level ≥ 1.0 g/dL, or
Urine M-protein level ≥ 200 mg/24 hours, or
Adoptive T-cell therapy (e.g., CAR T-cell therapy) at any time prior to enrollment.
Bispecific antibody, investigational or approved, irrespective of its target, at any time prior to enrollment.
Use of talquetamab prior to enrollment.
Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.